Effect of a biomimetic pathogen adsorbing device on inflammatory biomarkers in COVID-19 patients
Jan Schmieszek
Department of Respiratory, Sleep and Intensive Care Medicine, Siloah Hospital, Hannover, Germany
Search for more papers by this authorCorresponding Author
Thomas Fuehner
Department of Respiratory, Sleep and Intensive Care Medicine, Siloah Hospital, Hannover, Germany
Department of Respiratory Medicine and German Centre for Lung Research (DZL/BREATH), Hannover Medical School, Hannover, Germany
Correspondence
Thomas Fuehner, KRH Klinikum Siloah, Klinik fuer Pneumologie, Schlaf- und Intensivmedizin, Stadionbruecke 4, 30459 Hannover, Germany.
Email: [email protected]
Search for more papers by this authorIsabelle Renger
Department of Respiratory, Sleep and Intensive Care Medicine, Siloah Hospital, Hannover, Germany
Search for more papers by this authorTobias Welte
Department of Respiratory Medicine and German Centre for Lung Research (DZL/BREATH), Hannover Medical School, Hannover, Germany
Search for more papers by this authorJan Menne
Department of Nephrology, Angiology, and Rheumatology, Siloah Hospital, Hannover, Germany
Search for more papers by this authorJan Fuge
Department of Respiratory Medicine and German Centre for Lung Research (DZL/BREATH), Hannover Medical School, Hannover, Germany
Search for more papers by this authorMaria P. van't Klooster
Department of Respiratory, Sleep and Intensive Care Medicine, Siloah Hospital, Hannover, Germany
Search for more papers by this authorAndrea Paul
Department of Respiratory, Sleep and Intensive Care Medicine, Siloah Hospital, Hannover, Germany
Search for more papers by this authorAlina Siegert
Department of Nephrology, Rheumatology, Blood Purification, Academic Teaching Hospital Braunschweig, Braunschweig, Germany
Search for more papers by this authorDan-Nicolae Borchina
Department of Nephrology, Rheumatology, Blood Purification, Academic Teaching Hospital Braunschweig, Braunschweig, Germany
Search for more papers by this authorChristine S. Falk
Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany
Search for more papers by this authorJan T. Kielstein
Department of Nephrology, Rheumatology, Blood Purification, Academic Teaching Hospital Braunschweig, Braunschweig, Germany
Search for more papers by this authorJan Schmieszek
Department of Respiratory, Sleep and Intensive Care Medicine, Siloah Hospital, Hannover, Germany
Search for more papers by this authorCorresponding Author
Thomas Fuehner
Department of Respiratory, Sleep and Intensive Care Medicine, Siloah Hospital, Hannover, Germany
Department of Respiratory Medicine and German Centre for Lung Research (DZL/BREATH), Hannover Medical School, Hannover, Germany
Correspondence
Thomas Fuehner, KRH Klinikum Siloah, Klinik fuer Pneumologie, Schlaf- und Intensivmedizin, Stadionbruecke 4, 30459 Hannover, Germany.
Email: [email protected]
Search for more papers by this authorIsabelle Renger
Department of Respiratory, Sleep and Intensive Care Medicine, Siloah Hospital, Hannover, Germany
Search for more papers by this authorTobias Welte
Department of Respiratory Medicine and German Centre for Lung Research (DZL/BREATH), Hannover Medical School, Hannover, Germany
Search for more papers by this authorJan Menne
Department of Nephrology, Angiology, and Rheumatology, Siloah Hospital, Hannover, Germany
Search for more papers by this authorJan Fuge
Department of Respiratory Medicine and German Centre for Lung Research (DZL/BREATH), Hannover Medical School, Hannover, Germany
Search for more papers by this authorMaria P. van't Klooster
Department of Respiratory, Sleep and Intensive Care Medicine, Siloah Hospital, Hannover, Germany
Search for more papers by this authorAndrea Paul
Department of Respiratory, Sleep and Intensive Care Medicine, Siloah Hospital, Hannover, Germany
Search for more papers by this authorAlina Siegert
Department of Nephrology, Rheumatology, Blood Purification, Academic Teaching Hospital Braunschweig, Braunschweig, Germany
Search for more papers by this authorDan-Nicolae Borchina
Department of Nephrology, Rheumatology, Blood Purification, Academic Teaching Hospital Braunschweig, Braunschweig, Germany
Search for more papers by this authorChristine S. Falk
Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany
Search for more papers by this authorJan T. Kielstein
Department of Nephrology, Rheumatology, Blood Purification, Academic Teaching Hospital Braunschweig, Braunschweig, Germany
Search for more papers by this authorChristine S. Falk and Jan T. Kielstein are contributed equally to this study.
Abstract
Introduction
The Seraph 100 Microbind Affinity blood filter eliminate bacteria, viruses, fungi and toxins from blood stream.
Methods
This is a prospective multicenter observational biomarker trial in PCR-positive SARS-CoV-2 patients with acute respiratory failure. Biomarkers were sequentially tested at three time points.
Results
Forty-two patients with SARS-CoV-2 detected by PCR with acute respiratory failure were included. When receiving hemoperfusion treatment, 27 (64%) patients were on mechanical ventilation, 41 (98%) patients were treated in the ICU. The 3-month survival was 52%. After one hemoperfusion treatment cycle, D-dimer (p = 0.014), hemoglobin (p = 0.003) and LDH (p = 0.001) concentrations were significantly reduced 4 days after treatment. From the multiplex assay IL-1b, CXCL8/ IL-8, IL-10, IL-13, IL-15, CCL11/Eotaxin, G-CSF, and CXCL10/IP-10 were significantly reduced 1 h after treatment, however not 4 days later.
Conclusion
Hemoperfusion with Seraph 100 Microbind Affinity Filter in patients with severe COVID-19 can transiently reduce several inflammatory biomarkers in the blood.
CONFLICT OF INTEREST STATEMENT
Jan T. Kielstein received research support from ExThera Medical. For all other authors, no conflicts of interest arise in connection with this manuscript.
REFERENCES
- 1Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020; 383: 2603–2615.
- 2Baden LR, el Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021; 384: 403–416.
- 3Magen O, Waxman JG, Makov-Assif M, Vered R, Dicker D, Hernán MA, et al. Fourth dose of BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2022; 386(17): 1603–1614.
- 4 The RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsel L, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021; 384(8): 693–704.
- 5Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral Nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022; 386(15): 1397–1408.
- 6Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med. 2021;385(23):e81.
- 7Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody Sotrovimab. N Engl J Med. 2021; 385: 1941–1950.
- 8 Group C-C. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med. 2021; 9(3): 295–304.
- 9Seffer MT, Cottam D, Forni LG, Kielstein JT. Heparin 2.0: a new approach to the infection crisis. Blood Purif. 2020; 50: 1–7.
- 10Sullivan DJ, Gebo KA, Shoham S, Bloch EM, Lau B, Shenoy AG, et al. Early outpatient treatment for Covid-19 with convalescent plasma. N Engl J Med. 2022; 386(18): 1700–1711.
- 11Stockmann H, Thelen P, Stroben F, Pigorsch M, Keller T, Krannich A, et al. CytoSorb rescue for COVID-19 patients with vasoplegic shock and multiple organ failure: a prospective, open-label, randomized controlled pilot study. Crit Care Med. 2022; 50: 964–976.
- 12Supady A, Weber E, Rieder M, et al. Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial. 2021; 9(7): 755–762.
- 13Honore PM, Barreto Gutierrez L, Kugener L, Redant S, Attou R, Gallerani A, et al. Plasma exchange in critically ill COVID-19 patients improved inflammation, microcirculatory clot formation, and hypotension, thereby improving clinical outcomes: fact or fiction? Crit Care. 2020; 24(1): 551.
- 14Doevelaar AAN, Bachmann M, Hölzer B, Seibert FS, Rohn BJ, Bauer F, et al. von Willebrand factor Multimer formation contributes to Immunothrombosis in coronavirus disease 2019. Crit Care Med. 2021; 49: e512–e520.
- 15Tang K, Wu L, Luo Y, Gong B. Quantitative assessment of SARS-CoV-2 RNAemia and outcome in patients with coronavirus disease 2019. J Med Virol. 2021; 93: 3165–3175.
- 16Jacobs JL, Bain W, Naqvi A, Staines B, Castanha PMS, Yang H, et al. SARS-CoV-2 viremia is associated with COVID-19 severity and predicts clinical outcomes. Clin Infect Dis. 2021.
- 17Bermejo-Martin JF, González-Rivera M, Almansa R, Micheloud D, Tedim AP, Domínguez-Gil M, et al. Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19. Crit Care. 2020; 24(1): 691.
- 18Kielstein JT, Borchina DN, Fuhner T, Hwang S, Mattoon D, Ball AJ. Hemofiltration with the seraph((R)) 100 microbind((R)) affinity filter decreases SARS-CoV-2 nucleocapsid protein in critically ill COVID-19 patients. Crit Care. 2021; 25(1): 190.
- 19Schmidt JJ, Borchina DN, van't Klooster M, Bulhan-Soki K, Okioma R, Herbst L, et al. Interim-analysis of the COSA (COVID-19 patients treated with the seraph(R) 100 microbind(R) affinity filter) registry. Nephrol Dial Transplant. 2022; 37(4):673–680.
- 20Chitty SA, Mobbs S, Rifkin BS, Stogner SW, Lewis MS, Betancourt J, et al. A multicenter evaluation of the seraph 100 microbind affinity blood filter for the treatment of severe COVID-19. Crit Care Explor. 2022; 4(4):e0662.
- 21Pape A, Kielstein JT, Kruger T, Fuhner T, Brunkhorst R. Treatment of a critically ill COVID-19 patient with the seraph 100 microbind affinity filter. TH Open. 2021; 5(2): e134–e138.
- 22Olson SW, Oliver JD, Collen J, Bunin J, Gleeson TD, Foster BE, et al. Treatment for severe coronavirus disease 2019 with the Seraph-100 microbind affinity blood filter. Crit Care Explor. 2020; 2(8):e0180.
- 23Sandoval D, Rama I, Quero M, Hueso M, Gomez F, Cruzado JM. Treatment for severe COVID-19 with a biomimetic sorbent haemoperfusion device in patients on haemodialysis. Clin Kidney J. 2021; 14(5): 1475–1477.
- 24Ebeyer-Masotta M, Eichhorn T, Weiss R, Semak V, Lauková L, Fischer MB, et al. Heparin-functionalized adsorbents eliminate central effectors of immunothrombosis, including platelet factor 4, high-mobility group box 1 protein and histones. Int J Mol Sci. 2022; 23(3):1823.
- 25Sasson J, Donlan AN, Ma JZ, et al. Safety and efficacy of Dupilumab for the treatment of hospitalized patients with moderate to severe COVID 19: a phase IIa trial. medRxiv. 2022;9(8):ofac343.
- 26Alshammary AF, Alsughayyir JM, Alharbi KK, Al-Sulaiman AM, Alshammary HF, Alshammary HF. T-cell subsets and Interleukin-10 levels are predictors of severity and mortality in COVID-19: a systematic review and meta-analysis. Front Med (Lausanne). 2022; 9:852749.
- 27Elemam NM, Hammoudeh S, Salameh L, Mahboub B, Alsafar H, Talaat IM, et al. Identifying immunological and clinical predictors of COVID-19 severity and sequelae by mathematical modeling. Front Immunol. 2022; 13:865845.
- 28Peart Akindele N, Kouo T, Karaba AH, Gordon O, Fenstermacher KZJ, Beaudry J, et al. Distinct cytokine and chemokine dysregulation in hospitalized children with acute coronavirus disease 2019 and multisystem inflammatory syndrome with similar levels of nasopharyngeal severe acute respiratory syndrome coronavirus 2 shedding. J Infect Dis. 2021; 224(4): 606–615.
- 29Criner GJ, Lang FM, Gottlieb RL, Mathews KS, Wang TS, Rice TW, et al. Anti-GM-CSF monoclonal antibody Gimsilumab for COVID-19 pneumonia: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2022; 205: 1290–1299.
- 30Guasp M, Muñoz-Sánchez G, Martínez-Hernández E, Santana D, Carbayo Á, Naranjo L, et al. CSF biomarkers in COVID-19 associated encephalopathy and encephalitis predict long-term outcome. Front Immunol. 2022; 13:866153.
- 31Zeng Z, Yu H, Chen H, Qi W, Chen L, Chen G, et al. Longitudinal changes of inflammatory parameters and their correlation with disease severity and outcomes in patients with COVID-19 from Wuhan, China. Crit Care. 2020; 24(1): 525.
- 32Ruhl L, Pink I, Kühne JF, Beushausen K, Keil J, Christoph S, et al. Endothelial dysfunction contributes to severe COVID-19 in combination with dysregulated lymphocyte responses and cytokine networks. Signal Transduct Target Ther. 2021; 6(1): 418.
- 33Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223): 507–513.
- 34Dorward DA, Russell CD, Um IH, Elshani M, Armstrong SD, Penrice-Randal R, et al. Tissue-specific immunopathology in fatal COVID-19. Am J Respir Crit Care Med. 2021; 203(2): 192–201.
- 35Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021; 384(1): 20–30.
- 36Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021; 9(12): 1407–1418.
Citing Literature
